# A new approach in protein phosphorylation for Nanofitin radiolabeling

# <u>Marine Goux<sup>[1,2,3]</sup></u>, Alain Defontaine<sup>[1]</sup>, Amina Fateh<sup>[1]</sup>, Mathieu Cinier<sup>[2]</sup> and Charles Tellier<sup>[1]</sup>

<sup>[1]</sup>Unité de Fonctionnalité et Ingénierie des Protéines, University of Nantes, France ; <sup>[2]</sup>Affilogic SAS, Nantes, France and <sup>[3]</sup>Cyclotron Research Center, University of Liège, Belgium

### INTRODUCTION

Recently, new strategies emerged in the field of monoclonal antibodies radiolabeling for PET imaging with the use of positron emitter such as **zirconium-89** or **gallium-68**<sup>[1]</sup>. Despite their important role in the therapeutic world, antibodies have many disadvantages related to their structure. Moreover, conjugation of chelating agent often occurs on lysines, which is non-regioselective and leads to a heterogeneous mixture of products. In addition, the slow clearance of antibodies can be a problem to obtain a good contrast when they are used in imaging.


To address these different limitations, we developed a **chemistry-free chelating system** consisting of a highly phosphorylatable peptide tag. A specific phosphorylation step, with the alpha subunit of the casein kinase II (CKIIa), can generate a nanocluster of four phosphates that can interact strongly with metal ions like zirconium<sup>[2]</sup>.

## WHAT ARE NANOFITINS ?

Small Protein: 10kDa (rapid clearance)

pH stability: 0-12

Temperature Tm≈80°C Stability:



1) Adapt the labeling tag to the stereoselective chelation of radionuclides for PET imaging. 2) Genetically fuse the tag to a Nanofitin, a protein scaffold developed as an alternative to antibodies, to ensure an efficient targeting of the radionuclide.

Low (Generated *in vitro* and Production produced in bacteria)


0,1nM

#### RESULTS

**OBJECTIVES:** 

#### CHELATION WITH RADIONUCLIDES

To optimize the sequence of the phosphorylatable tag, we studied the chelation of different mimetic peptides with a lanthanide (terbium).




DEVELOPMENT OF AN IN VIVO CO-EXPRESSION AND PHOSPHORYLATION SYSTEM

cost:


Affinity:

In early development, the phosphorylation was realized *in vitro*. In order to save purification steps, we developed an *in vivo* phosphorylation system consisting in the co-expression of a Nanofitin® fused to the phosphorylatable tag (pNF) and the CKIIa.



• Effectiveness of the *in vivo* system was demonstrated both by


- Fluorescence increases as the peptide is phosphorylated.
- Chelation of the zirconium by the peptide tag was confirmed by a competition study.



Terbium(III) titration of mono- and tetra-


phosphorylated peptides in formic acid pH2

Terbium(III) titration of tri-phosphorylated peptide and competition with zirconium(IV) in formic acid pH2 (After removal of peptide and terbium fluorescence)




electrophoretic mobility shift assay and staining with a specific **phosphoprotein staining gel**: ProQDiamond®.

• Extra addition of ATP after lysis improve significantly the rate of phosphorylation.



To evaluate the phosphorylation rate we developped an isoelectric focusing method based on the fact that the pHi of the Nanofitin® decreases as the protein is phosphorylated. Such a technique allowed us to isolate the different phosphorylation states of the phospho-**Nanofitin**® (from 0 to 4 phospho-serine).



Equivalent of terbium per peptide	Equivalent of terbium or terbium/zirconium (1:1) per peptide	PhosphoNanofitin®	4P 3P OP	
CONCLUSION				
relying on the specific interaction of much simpler and straightforward sy single step regioselective labeling for	of the <i>in vivo</i> system, we are developing a phosphop f phosphate moeity with gallium(III) or iron(III). The u ystem. Finally this fusion system of phosphate nanoclust r both zirconium-89 and gallium-68, together with a hig idies with peptide-gallium complex and phospho-Nanofi	use of a single tag for both the ter and a Nanofitin® will allow will stable targeting moiety. Co	the purification and the labeling ws us to combine the advantage Concerning the chelation experin	g will provide a es of an original ments, we have

<u>References</u> : <sup>[1]</sup> Heuveling D. A. *et al.* (2011), Oral Oncology, 47, pp. 2–7 ; <sup>[2]</sup> Cinier M. *et al.* (2012), Journal of Biological Inorganic Chemistry, 17, pp. 399–407 ; <sup>[3]</sup> PhosphoProtein Handbook (2011), QIAGEN®; <sup>[4]</sup> Machida M. et al. (2007), FEBS Journal, 274, pp. 1576–1587



#### **UFIP FRE CNRS 3478//AFFILOGIC SAS** 2 rue de la Houssinière, 44322 Nantes, France

**Cyclotron Research Center** Allée du 6 Août 4000, Liège, Belgium

marine.goux@univ-nantes.fr Contact :







### Journées scientifiques



December 09-10, 2013